Seres Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
MCRB$1.56-8.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
Item 15. Exhibits and Financial Statements Schedules
(a)(1) Financial Statements.
See the “Index to Consolidated Financial Statements” on page F-1 below for the list of financial statements filed as part of this report.
(a)(2) Financial Statement Schedules.
All schedules have been omitted because they are not required or because the required information is given in the Consolidated Financial Statements or Notes thereto set forth below beginning on page F-1.
(a)(3) Exhibits.
The following is a list of all exhibits filed as a part of this Annual Report on Form 10-K.
| Incorporated by Reference · Filed/ | ||||||
|---|---|---|---|---|---|---|
| ExhibitNumber | Exhibit Description | Form | File No. | Exhibit | FilingDate | FurnishedHerewith |
| 2.1^ | Asset Purchase Agreement, dated August 5, 2024, by and between the Registrant and Société des Produits Nestlé S.A. | 8-K | 001-37465 | 2.1 | 8/6/24 | |
| 3.1 | Restated Certificate of Incorporation | 8-K | 001-37465 | 3.1 | 7/1/15 | |
| 3.2 | Certificate of Amendment to Restated Certificate of Incorporation of Registrant, dated June 27, 2023 | 8-K | 001-37465 | 3.1 | 6/28/23 | |
| 3.3 | Certificate of Amendment to Restated Certificate of Incorporation of Registrant, dated April 5, 2024 | 8-K | 001-37465 | 3.1 | 4/8/24 | |
| 3.4 | Certificate of Amendment to Restated Certificate of Incorporation of Registrant, dated April 21, 2025 | 8-K | 001-37465 | 3.1 | 4/22/25 | |
| 3.5 | Amended and Restated Bylaws | 8-K | 001-37465 | 3.1 | 1/2/24 | |
| 4.1 | Specimen Stock Certificate evidencing the shares of common stock | S-1/A | 333-204484 | 4.2 | 6/16/15 | |
| 4.2 | Description of Capital Stock | * | ||||
| 4.3 | Form of Warrant, dated April 27, 2023, issued by the Registrant to the Lenders, together with a schedule of warrant holders | 8-K | 001-37465 | 4.1 | 4/27/23 | |
| 10.1# | 2025 Incentive Award Plan, as amended and forms of award agreements thereunder | 8-K | 001-37465 | 10.1 | 4/14/25 | |
| 10.2# | 2015 Incentive Award Plan, as amended and forms of award agreements thereunder | 10-K | 001-37465 | 10.1 | 3/7/23 | |
| 10.3# | 2015 Employee Stock Purchase Plan | S-1/A | 333-204484 | 10.3 | 6/16/15 | |
| 10.4# | 2012 Stock Incentive Plan, as amended and form of option agreement thereunder | S-1 | 333-204484 | 10.1 | 5/27/15 | |
| 10.5# | 2022 Employment Inducement Award Plan and forms of award agreements thereunder | 10-K | 001-37465 | 10.4 | 3/7/23 | |
| 10.6# | Non-Employee Director Compensation Program | 10-Q | 001-37465 | 10.2 | 5/7/25 | |
| 10.7 | Lease, dated September 22, 2021, by and between the Registrant and HCP/KING 101 CPD LLC | 10-K | 001-37465 | 10.6 | 3/5/24 | |
| 10.8# | Second Amended and Restated Employment Agreement, dated January 29, 2021, by and between the Registrant and Eric D. Shaff | 8-K | 001-37465 | 10.1 | 2/1/21 | |
| 10.9# | Letter Agreement, dated July 21, 2025, by and between the Company and Eric D. Shaff | 10-Q | 001-37465 | 10.1 | 8/6/25 | |
| 10.10# | Amended and Restated Employment Agreement, dated January 29, 2021, by and between the Registrant and Thomas J. DesRosier | 8-K | 001-37465 | 10.2 | 2/1/21 | |
| 10.11# | Letter Agreement, dated July 21, 2025, by and between the Company and Thomas J. DesRosier | 10-Q | 001-37465 | 10.3 | 8/6/25 | |
| 10.12# | Second Amended and Restated Employment Agreement, dated January 29, 2021, by and between the Registrant and Matthew R. Henn, Ph.D. | 8-K | 001-37465 | 10.3 | 2/1/21 | |
| 10.13# | Retention Agreement, dated October 5, 2025, by and between the Company and Matthew R. Henn, Ph.D. | 10-Q | 001-37465 | 10.1 | 11/5/25 | |
| 10.14# | Letter Agreement dated March 2, 2026, by and between the Company and Matthew Henn, Ph.D. | 8-K | 001-37465 | 10.2 | 3/2/26 | |
| 10.15# | Amended and Restated Employment Agreement, dated January 29, 2021, by and between the Registrant and Teresa L. Young | 10-K | 001-37465 | 10.13 | 3/2/21 | |
| 10.16# | Retention Agreement, dated October 2, 2025, by and between the Company and Teresa L. Young | 10-Q | 001-37465 | 10.2 | 11/5/25 | |
| 10.17# | Employment Agreement, dated February 24, 2024, by and between the Registrant and Marella Thorell | 10-Q | 001-37465 | 10.1 | 5/8/24 | |
| 10.18# | Letter Agreement, dated July 21, 2025, by and between the Company and Marella Thorell | 10-Q | 001-37465 | 10.2 | 8/6/25 | |
| 10.19# | Amended and Restated Employment Agreement, dated March 18, 2025, by and between the Company and Kelly M. Brady | * | ||||
| 10.20# | Letter Agreement dated March 2, 2026, by and between the Company and Kelly M. Brady | 8-K | 001-37465 | 10.1 | 3/2/26 | |
| 10.21# | Employment Letter Agreement dated March 2, 2026, by and between the Company and Richard N. Kender | 8-K | 001-37465 | 10.3 | 3/2/26 | |
| 10.22 | Securities Purchase Agreement, dated September 30, 2024, by and between Seres Therapeutics, Inc. and Société des Produits Nestlé S.A. | 8-K | 001-37465 | 10.1 | 10/1/24 | |
| 10.23† | Transition Services Agreement, dated September 30, 2024, by and between Seres Therapeutics, Inc. and Nestlé Enterprises S.A. | 8-K | 001-37465 | 10.2 | 10/1/24 | |
| 10.24 | Cross-License Agreement, dated September 30, 2024, by and between Seres Therapeutics, Inc. and Société des Produits Nestlé S.A. | 8-K | 001-37465 | 10.3 | 10/1/24 | |
| 10.25 | Securities Purchase Agreement, dated August 12, 2020 by and between the Company and Société des Produits Nestlé S.A. | 8-K | 001-37465 | 10.1 | 8/14/20 | |
| 10.26# | Form of Performance Option Agreement under the 2015 Incentive Award Plan | 10-Q | 001-37465 | 10.6 | 5/8/24 | |
| 19.1 | Seres Therapeutics, Inc. Insider Trading Compliance Policy | 10-K | 001-37465 | 19.1 | 3/13/25 | |
| 21.1 | Subsidiaries of Seres Therapeutics, Inc. | 10-K | 001-37465 | 21.1 | 3/2/20 | |
| 23.1 | Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm | * | ||||
| 31.1 | Rule 13a-14(a)/15d-14(a) Certification of Interim Chief Executive Officer | * | ||||
| 31.2 | Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer | * | ||||
| 32.1 · Section 1350 Certification of Interim Chief Executive Officer · ** | ||||||
|---|---|---|---|---|---|---|
| 32.2 · Section 1350 Certification of Chief Financial Officer · ** | ||||||
| 97.1# | Policy for Recovery of Erroneously Awarded Compensation | 10-K | 001-37465 | 97.1 | 3/5/24 | |
| 101.INS | Inline XBRL Instance Document- the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document | * | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | * | ||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | * | ||||
- Filed herewith.
** Furnished herewith.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.